FAQ: Oncotelic's Nanomedicine Breakthrough in Cancer Drug Delivery
Summary
Oncotelic Therapeutics is advancing precision nanomedicine with its proprietary 20nm Deciparticle™ platform, which enhances tumor targeting and drug efficacy for cancer treatments. The technology achieves full bioavailability of drugs like Everolimus and accelerates clinical development through rapid IND capabilities.
What is the main focus of Oncotelic’s nanomedicine technology?
Oncotelic is advancing precision nanomedicine with its proprietary Deciparticle™ platform, which uses 20nm nanoparticles to enhance targeted drug delivery for cancer treatments, specifically beginning human trials for Sapu003, a nanoparticle formulation of Everolimus (Afinitor®).
Why is particle size important in cancer drug delivery?
Particle size is critical because conventional chemotherapy exposes healthy tissues to cytotoxic agents causing severe side effects, while oral targeted therapies often fail to reach tumors at therapeutic concentrations, making nanomedicine’s precise particle sizing essential for effective tumor targeting.
How does the 20nm Deciparticle™ technology improve drug delivery compared to oral formulations?
The 20nm Deciparticle™ achieves full bioavailability with intravenous delivery of Everolimus, maximizing tumor targeting and efficacy compared to only 10% absorption with oral formulations.
What is Sapu003 and what stage of development is it in?
Sapu003 is a 20nm nanoparticle formulation of Everolimus (Afinitor®) that has begun Phase 1 clinical trials after receiving Australian HREC approval.
How is Oncotelic accelerating its clinical development pipeline?
Through a strategic partnership with Medicilon, Oncotelic has established a rapid IND platform that supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle™ drug candidates to reach clinical testing quickly.
What are the key benefits of Oncotelic’s nanoparticle technology?
The technology provides enhanced tumor targeting, full drug bioavailability, reduced side effects compared to conventional chemotherapy, and accelerated clinical development through their rapid IND platform.
Where can investors find the latest news and updates about Oncotelic?
The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC.
What is BioMedWire and how is it related to this content?
BioMedWire is a specialized communications platform focusing on biotechnology and biomedical sciences developments, and it is part of the Dynamic Brand Portfolio at IBN that distributes this type of content through various channels including wire solutions, editorial syndication, and social media distribution.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 259992